WARNING

Portrazza is a medication used in the treatment of non-small cell lung cancer (NSCLC). Its generic name is necitumumab. Like any medication, Portrazza comes with potential risks and side effects. It’s important to note that this information is not a substitute for professional medical advice, and individuals should consult their healthcare provider for personalized guidance. Here are some potential risks associated with Portrazza:

• Infusion Reactions: Portrazza can cause infusion reactions, which may include symptoms like fever, chills, rash, or difficulty breathing. These reactions usually occur during or within 24 hours of the infusion.
• Hypomagnesemia: Portrazza may lead to low magnesium levels in the blood, which can cause symptoms such as muscle spams, irregular heartbeat, and seizures.
• Thromboembolism: There is an increased risk of blood clots with Portrazza, which can lead to serious conditions such as stroke or heart attack.
• Dermatologic Toxicities: Skin-related side effects, including rash and acneiform dermatitis, may occur. In severe cases, skin reactions may require dose modifications or discontinuation of the drug.
• Increased Toxicity with Platinum-Based Chemotherapy: When Portrazza is used in combination with platinum-based chemotherapy, there may be an increased risk of toxicities, including gastrointestinal perforations, fistulas, and infections.
• Pulmonary Toxicity: Portrazza has been associated with pulmonary toxicity, including interstitial lung disease and pneumonitis.
• Fetal Harm: Portrazza can cause fetal harm when administered to pregnant individuals. It is important to use effective contraception during treatment and for a period after discontinuation.
• Limitations in Survival Benefit: The use of Portrazza may not significantly improve overall survival, and its benefits should be carefully weighed against the potential risks.

Patients should discuss their medical history and any existing health conditions with their healthcare provider before starting Portrazza. Regular monitoring and communication with the healthcare team are crucial to manage potential risks and optimize the benefits of the treatment.

Why is this medication prescribed?

Portrazza (generic name: necitumumab) is prescribed as a part of the treatment plan for individuals with advanced-stage non-small cell lung cancer (NSCLC), specifically for those with squamous histology. It is typically used in combination with other chemotherapy medications, such as gemcitabine and cisplatin.

The primary aim of Portrazza is to inhibit the activity of the epidermal growth factor receptor (EGFR), a protein that is overexpressed in some types of cancer cells. By targeting EGFR, Portrazza aims to slow down or inhibit the growth of cancer cells.

How should this medicine be used?

Here are general guidelines for using Portrazza:

• Administration: Portrazza is administered intravenously (IV), meaning it is given directly into the bloodstream through a vein.
• Combination Therapy: It is usually used in combination with gemcitabine and cisplatin, and the entire regimen is administered in cycles. The specific dosage and schedule will be determined by the treating oncologist based on the patient’s health, overall treatment plan, and individual factors.
• Pre-Medication: Patients may be given pre-medications, such as antihistamines and corticosteroids, to help prevent or manage potential infusion reactions.
• Monitoring: Regular monitoring is essential during treatment to assess the patient’s response to the medication and to manage any potential side effects.
• Fertility and Pregnancy: Portrazza may cause fetal harm, so effective contraception is important during treatment, and patients should be advised not to become pregnant while on Portrazza. If pregnancy occurs, patients should inform their healthcare provider immediately.

It’s crucial for patients to follow their healthcare provider’s instructions precisely and to communicate any concerns, side effects, or changes in their health during treatment. Dosages and treatment plans may vary based on individual health conditions, and the healthcare team will monitor for any adverse reactions or adjustments needed throughout the course of treatment. As with any cancer treatment, the decision to use Portrazza should be made in consultation with a qualified oncologist who can assess the potential benefits and risks for each individual patient.

Other uses for this medicine

Portrazza (necitumumab) is primarily used for the treatment of advanced-stage non-small cell lung cancer (NSCLC) with squamous histology. As of last update, there are no widely recognized alternative uses for Portrazza beyond its approved indication for NSCLC.

What special precautions should I follow?

Regarding special precautions for using Portrazza, it’s important for healthcare providers and patients to consider the following:

• Infusion Reactions: Portrazza can cause infusion reactions, which may include symptoms like fever, chills, rash, or difficulty breathing. Patients are usually monitored closely during and after the infusion for any signs of reactions.
• Hypomagnesemia: Regular monitoring of magnesium levels is recommended during treatment, as Portrazza may lead to low magnesium levels in the blood. Symptoms of hypomagnesemia include muscle spasms, irregular heartbeat, and seizures.
• Thromboembolism: There is an increased risk of blood clots with Portrazza, which can lead to serious conditions such as stroke or heart attack. Patients with a history of blood clotting disorders or cardiovascular issues may require careful monitoring.
• Pulmonary Toxicity: Portrazza has been associated with pulmonary toxicity, including interstitial lung disease and pneumonitis. If patients experience new or worsening respiratory symptoms, they should promptly notify their healthcare provider.
• Dermatologic Toxicities: Skin-related side effects, including rash and acneiform dermatitis, may occur. Severe reactions may necessitate dose adjustments or discontinuation of the drug.
• Fetal Harm: Portrazza can cause fetal harm if administered to pregnant individuals. Effective contraception is essential during treatment, and patients should be advised not to become pregnant while on Portrazza.
• Combination Therapy: Portrazza is often used in combination with other chemotherapy agents, and the overall treatment plan may involve managing potential toxicities associated with the combination.
• Monitoring and Regular Check-ups: Regular monitoring of blood counts, electrolytes, and other relevant parameters is crucial during treatment. Patients should attend scheduled follow-up appointments to assess treatment efficacy and manage potential side effects.

Patients should inform their healthcare provider about their medical history, including any existing health conditions and medications they are taking, before starting Portrazza. Additionally, patients should promptly report any new or worsening symptoms during treatment.

It’s important to note that information about medications can evolve, and new updates may have occurred since last update. Therefore, individuals should consult with their healthcare provider for the most current and personalized information based on their specific health circumstances.

What special dietary instructions should I follow?

There are no specific dietary restrictions or instructions directly associated with Portrazza. However, individual healthcare providers may provide specific guidance based on the patient’s overall health and any pre-existing conditions. It’s advisable to discuss dietary considerations with your healthcare team.

What should I do if I forget a dose?

If you forget a dose of Portrazza, contact your healthcare provider promptly for guidance. It is essential to adhere to the prescribed schedule, but your healthcare provider will advise on the appropriate course of action based on the specific circumstances.

What side effects can this medication cause?

Portrazza (necitumumab) is a medication used in the treatment of advanced-stage non-small cell lung cancer (NSCLC) with squamous histology. Like many cancer therapies, it can cause side effects. It’s important to note that not everyone will experience these side effects, and the severity can vary among individuals. Common side effects of Portrazza may include:

• Infusion Reactions: Infusion-related reactions are common and may include symptoms such as fever, chills, rash, or difficulty breathing. These reactions typically occur during or shortly after the infusion and are closely monitored by healthcare providers.
• Hypomagnesemia: Portrazza may lead to low magnesium levels in the blood, which can cause symptoms such as muscle spasms, irregular heartbeat, and seizures.
• Thromboembolism: There is an increased risk of blood clots, which can lead to serious conditions such as stroke or heart attack.
• Pulmonary Toxicity: Portrazza has been associated with pulmonary toxicity, including interstitial lung disease and pneumonitis. Patients may experience new or worsening respiratory symptoms.
• Dermatologic Toxicities: Skin-related side effects are common and may include rash and acneiform dermatitis. Severe reactions may necessitate dose adjustments or discontinuation of the drug.
• Gastrointestinal Issues: Nausea, vomiting, diarrhea, and abdominal pain are possible side effects.
• Fatigue: Weakness and fatigue are common during cancer treatment.
• Electrolyte Imbalance: Portrazza may affect electrolyte levels, leading to abnormalities that require monitoring and management.
• Decreased Appetite: Some individuals may experience a decrease in appetite.

It’s important for patients to communicate any side effects or symptoms to their healthcare provider promptly. The healthcare team can provide guidance on managing side effects and may adjust the treatment plan if needed.

This list is not exhaustive, and other side effects may occur. Additionally, the information provided here is based on last update, and new developments may have occurred since then. Patients should consult their healthcare provider for the most current information and guidance tailored to their specific health condition.

What should I know about storage and disposal of this medication?

Here are important considerations regarding the storage and disposal information related to Portrazza (necitumumab):

Storage:

• Refrigeration: Portrazza is typically supplied as a solution for intravenous infusion and may require refrigeration. Follow the storage instructions provided by the healthcare provider or on the medication label.
• Protect from Light: Some medications may be sensitive to light. If specified, store Portrazza away from direct light exposure.
• Keep Out of Reach of Children: Store medications in a secure place, out of reach of children and pets.

Disposal:

• Medical Waste Disposal: Dispose of used needles and other medical waste in accordance with local regulations. Your healthcare provider or pharmacist can provide guidance on proper disposal.
• Unused Medication: Do not keep unused Portrazza. Follow specific disposal instructions provided by your healthcare provider or pharmacist.

In case of emergency/overdose

In case of an emergency or overdose, it is crucial to seek immediate medical attention. Contact your local poison control center (in the U.S., call 1-800-222-1222) or go to the nearest emergency room.

What other information should I know?

• Follow Healthcare Provider Instructions: Adhere to the prescribed dosage and schedule as instructed by your healthcare provider. Do not adjust the dosage without consulting your healthcare team.
• Regular Monitoring: Attend scheduled appointments for monitoring of your health, blood counts, and other relevant parameters. Report any unusual symptoms or side effects to your healthcare provider promptly.
• Pregnancy and Contraception: Portrazza can cause fetal harm, and effective contraception is crucial during treatment. If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits with your healthcare provider.
• Inform Healthcare Providers: Inform all healthcare providers involved in your care about the medications you are taking, including Portrazza, to avoid potential interactions.
• Allergies and Pre-existing Conditions: Inform your healthcare provider of any allergies or pre-existing conditions, as well as all medications, supplements, and herbal products you are taking.
• Patient Assistance Programs: Explore patient assistance programs or support services that may be available to help with the cost of the medication.

Always consult with your healthcare provider or pharmacist for the most up-to-date and personalized information related to Portrazza. They can provide guidance tailored to your specific health needs and circumstances.